Why invest

Our successful business model provides a solid platform for growth. We combine a diverse portfolio with excellent financial discipline to deliver outstanding value for shareholders.

A firm foundation for future growth

  • Leading supplier of both generic injectable and non-injectable products in the US
  • Leading market position in MENA (second largest pharmaceutical company by sales) and a growing presence in Europe
  • Trusted partner known for our commitment to quality and reliability of supply
  • Broad portfolio of high-quality products 
  • Agile supply chain, flexible manufacturing and leading technical capabilities
Highlights
$ 2,875 m Group core revenue
$ 707 m Group core operating profit
18 % Return on capital invested

An increasingly diverse portfolio and pipeline

  • Growing presence in specialty and complex products, which offer less competition and more potential for future margin growth
  • Focus on higher-value therapeutic areas such as cardiovascular, central nervous system (CNS) and oncology
  • Annual investment in R&D to ensure we are consistently
    launching new products across our markets
  • Strong track record of value-creating partnerships, strategic
    acquisitions and geographic expansion, to enhance pipeline
    and access to new markets
Highlights
5 % R&D spend as % of revenue
157 launches in 2023 across our markets
250 + projects in pipeline

A strong balance sheet and robust cash generation

  • Good cash flow generation, with $608 million operating cash flow in 2023
  • Highly disciplined approach to cash management and acquisitions
  • Strong balance sheet that provides financial flexibility to
    support future growth, and low leverage of 1.2x net debt/
    core EBITDA
Highlights
1.2 x net debt/core EBITDA
$ 608 m operating cash flow
21 % operating cash flow/revenue

A proven track record of delivery for shareholders

  • A clear vision for growth
  • Group revenue compound annual growth rate (CAGR) of 7% and core EBITDA CAGR of 8% since 2018
  • Total shareholder return of 76% over the last ten years
  • Progressively increasing dividend
Highlights
17.7 % return on invested capital
5 % group revenue growth at five-year CAGR
76 % TSR over last ten years

All figures for year ending 31 December 2023. 

New

Hikma continues strong strategic execution and reiterates guidance

Press Release, Financial Results 07 November 2024
New

Hikma's leadership receives prestigious recognitions in 2024

Story, Leadership 22 October 2024

Empowering lives - Hikma’s regional blood donation drives across MENA

Story, Responsibility 21 October 2024
New

Hikma celebrates 40 years of Hatch-Waxman drug savings

Insight, Corporate 30 September 2024
New

Hikma: where our purpose inspires our people

Insight, Corporate 23 September 2024
New

Hikma launches Foscarnet Sodium Injection, in the US

Press Release, Product 23 September 2024

Hikma completes Xellia acquisition

Press Release, Corporate 10 September 2024

Hikma launches Clindamycin in 5% Dextrose Injection in the US

Press Release, Product 03 September 2024
New

Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA

Insight, Corporate 28 August 2024
New

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fenta...

Press Release, Product 20 August 2024
Related content

Recent results